Health & Beauty

On August 23, 2022, the World Health Organization (WHO) announced that China has passed the assessment of the National Regulatory System (NRA) for vaccines.

The WHO's assessment of the national vaccine regulatory system is an important measure and an effective means of assessing the national vaccine regulatory capacity. my country's vaccine supervision system has passed the evaluation twice in 2011 and 2014, and in July 2022, it will usher in a new round of comprehensive evaluation after the WHO's upgraded evaluation standards. The evaluation indicators have been greatly increased, the content is more comprehensive, and the standards are more stringent.

Through the evaluation, it not only means that China has a stable, well-functioning and complete and unified supervision system, which can ensure that the quality of vaccines produced, imported or circulated in China is controllable, safe and effective, but also an important basis for my country's vaccine exports to the world. WHO will pass the evaluation of the vaccine regulatory system as a precondition for purchasing vaccine products from the country, that is, only after the national regulatory system has passed the evaluation, the country's enterprises can apply for WHO pre-certification of vaccine products and include them in the procurement list of international organizations such as the United Nations. In addition, passing the evaluation is also an important reference for other countries to register and purchase vaccine products from other countries.

Since my country passed the assessment of the national vaccine supervision system for the first time, a number of domestic vaccines including live attenuated Japanese encephalitis vaccine, live attenuated vaccine of type I type III poliomyelitis, and inactivated hepatitis A vaccine have passed the WHO's vaccine pre-certification. , entered the international procurement list, purchased by UNICEF, GAVI and other international agencies, and related products have been exported to dozens of countries and regions. Since the outbreak of the novel coronavirus pneumonia, three novel coronavirus vaccines in my country have been included in the WHO emergency use list to help the global fight against the epidemic.

This time, my country's vaccine supervision system passed the WHO evaluation, which demonstrates that my country's vaccine supervision system is benchmarked against international standards, and its supervision capability and level have been improved. Good conditions have been created for my country's vaccine products to go abroad and help the development of public health in the world. China can play a more active role in global vaccine supply and contribute to promoting vaccine accessibility and affordability globally, especially in developing countries.